Company / PP&E (Net)
Veracyte, Inc. PP&E (Net) History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$17.7M
FY2022
5-year range
$15.1M / $17.7M
FY2018-FY2022
Trend
+17.2%
vs FY2021
Sector context
#116 of 135
Health Care
What the data says
Veracyte, Inc.'s pp&e (net) of $18M is lower than 86% of companies in the Health Care sector (FY2022). PP&E (Net) has increased for 3 consecutive years, from $9M in FY2019 to $18M in FY2022.
Based on SEC 10-K filings.
$18M in FY2022 with a 5-year CAGR of +12.8%.
Improved from $9M to $18M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +25.6%
- 5-Year CAGR
- +12.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 135This company $17.7M Sector average $1.4B
▼
-98.7% below sector average
Key checks
Key Insights
- Veracyte, Inc.'s pp&e (net) has grown for 3 consecutive years.
- 5-year CAGR of +12.8%, indicating consistent growth.
- In FY2022, pp&e (net) increased 17.2% year-over-year.
- Ranks #116 out of 135 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $17.7M | +17.2% |
| FY2021 | $15.1M | +67.9% |
| FY2020 | $9.0M | +0.6% |
| FY2019 | $8.9M | -0.1% |
| FY2018 | $8.9M | -7.7% |
| FY2017 | $9.7M | -15.6% |
| FY2016 | $11.5M | +11.3% |
As of FY2022 · SEC 10-K · Updated Feb 28, 2026